Yavar-70A, a novel water-in-oil adjuvant: A potency study in HPV-16E7d vaccine model
Objective(s): Adjuvants are some of the most important components used for vaccine formulation. In addition, the efficacy of vaccines is highly dependent on the nature of the adjuvants used. Therefore, new adjuvant formulations may help develop more potent vaccines. In the present study, the potency...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Mashhad University of Medical Sciences
2025-02-01
|
| Series: | Iranian Journal of Basic Medical Sciences |
| Subjects: | |
| Online Access: | https://ijbms.mums.ac.ir/article_25265_071c9e5e07dfbd3e4525287c835ce198.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850068345610567680 |
|---|---|
| author | Zeinab Mirzaei Soyar Sari Masoud Moghaddam Pour Seyed Mehdi Hassanzadeh Benjamin Damizadeh Morteza Taghizadeh Mehdi Mahdavi |
| author_facet | Zeinab Mirzaei Soyar Sari Masoud Moghaddam Pour Seyed Mehdi Hassanzadeh Benjamin Damizadeh Morteza Taghizadeh Mehdi Mahdavi |
| author_sort | Zeinab Mirzaei |
| collection | DOAJ |
| description | Objective(s): Adjuvants are some of the most important components used for vaccine formulation. In addition, the efficacy of vaccines is highly dependent on the nature of the adjuvants used. Therefore, new adjuvant formulations may help develop more potent vaccines. In the present study, the potency of an in-house and water-in-oil adjuvant (Yavar-70A) was compared with Montanide ISA 206 and Montanide ISA 266 in an HPV-16E7d vaccine model. Materials and Methods: Three HPV-16 E7d vaccines were formulated using three different adjuvants, Montanide ISA 206, Montanide ISA 266, and Yavar-70A, with standard protocols. Afterward, each formulation containing 10 μg of the E7d protein was administered thrice at two-week intervals to C57BL/6 mice. Serum levels of IFN-γ and IL-4 cytokines secreted from spleen cells, total IgG, and specific IgG1 and IgG2a isotypes were assessed using ELISA two weeks after the last immunization. Lymphocyte proliferative responses were also evaluated using the BrdU method.Results: The results indicated that the vaccine formulated using the Yavar-70A adjuvant showed the highest lymphocyte proliferation responses compared with other groups and higher IFN-γ cytokine release compared with that formulated using Montanide ISA 206. However, the vaccine formulated using Montanide ISA 206 induced the highest total IgG responses compared with other groups. Importantly, the vaccine formulated using Yavar-70A decreased IL-4 secretion compared with other vaccinated groups.Conclusion: The present study demonstrated that Yavar-70A induces cellular and humoral immunologic parameters against the HPV-16 E7d vaccine model comparable to commercialized oil-based adjuvants. |
| format | Article |
| id | doaj-art-01b61ebaa9d54d64bb5c4a151c83158e |
| institution | DOAJ |
| issn | 2008-3866 2008-3874 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Mashhad University of Medical Sciences |
| record_format | Article |
| series | Iranian Journal of Basic Medical Sciences |
| spelling | doaj-art-01b61ebaa9d54d64bb5c4a151c83158e2025-08-20T02:48:06ZengMashhad University of Medical SciencesIranian Journal of Basic Medical Sciences2008-38662008-38742025-02-0128222422910.22038/ijbms.2024.81654.1767125265Yavar-70A, a novel water-in-oil adjuvant: A potency study in HPV-16E7d vaccine modelZeinab Mirzaei0Soyar Sari1Masoud Moghaddam Pour2Seyed Mehdi Hassanzadeh3Benjamin Damizadeh4Morteza Taghizadeh5Mehdi Mahdavi6Department of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, IranDepartment of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, IranPoultry Viral Vaccines Research and Production Department, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization(AREEO), Karaj, IranDepartment of BCG Vaccine Production, Production and Research Complex, Pasteur Institute of Iran, Karaj, IranDepartment of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, IranDepartment of Medical Vaccine, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, IranAdvanced Therapy Medicinal Product (ATMP) Department, Breast Cancer Research Center, Motamed Cancer Institute, Academic Center for Education, Culture, and Research (ACECR), Tehran, IranObjective(s): Adjuvants are some of the most important components used for vaccine formulation. In addition, the efficacy of vaccines is highly dependent on the nature of the adjuvants used. Therefore, new adjuvant formulations may help develop more potent vaccines. In the present study, the potency of an in-house and water-in-oil adjuvant (Yavar-70A) was compared with Montanide ISA 206 and Montanide ISA 266 in an HPV-16E7d vaccine model. Materials and Methods: Three HPV-16 E7d vaccines were formulated using three different adjuvants, Montanide ISA 206, Montanide ISA 266, and Yavar-70A, with standard protocols. Afterward, each formulation containing 10 μg of the E7d protein was administered thrice at two-week intervals to C57BL/6 mice. Serum levels of IFN-γ and IL-4 cytokines secreted from spleen cells, total IgG, and specific IgG1 and IgG2a isotypes were assessed using ELISA two weeks after the last immunization. Lymphocyte proliferative responses were also evaluated using the BrdU method.Results: The results indicated that the vaccine formulated using the Yavar-70A adjuvant showed the highest lymphocyte proliferation responses compared with other groups and higher IFN-γ cytokine release compared with that formulated using Montanide ISA 206. However, the vaccine formulated using Montanide ISA 206 induced the highest total IgG responses compared with other groups. Importantly, the vaccine formulated using Yavar-70A decreased IL-4 secretion compared with other vaccinated groups.Conclusion: The present study demonstrated that Yavar-70A induces cellular and humoral immunologic parameters against the HPV-16 E7d vaccine model comparable to commercialized oil-based adjuvants.https://ijbms.mums.ac.ir/article_25265_071c9e5e07dfbd3e4525287c835ce198.pdfhpv-16-e7difn-γoil adjuvantsvaccine formulationyavar-70a |
| spellingShingle | Zeinab Mirzaei Soyar Sari Masoud Moghaddam Pour Seyed Mehdi Hassanzadeh Benjamin Damizadeh Morteza Taghizadeh Mehdi Mahdavi Yavar-70A, a novel water-in-oil adjuvant: A potency study in HPV-16E7d vaccine model Iranian Journal of Basic Medical Sciences hpv-16-e7d ifn-γ oil adjuvants vaccine formulation yavar-70a |
| title | Yavar-70A, a novel water-in-oil adjuvant: A potency study in HPV-16E7d vaccine model |
| title_full | Yavar-70A, a novel water-in-oil adjuvant: A potency study in HPV-16E7d vaccine model |
| title_fullStr | Yavar-70A, a novel water-in-oil adjuvant: A potency study in HPV-16E7d vaccine model |
| title_full_unstemmed | Yavar-70A, a novel water-in-oil adjuvant: A potency study in HPV-16E7d vaccine model |
| title_short | Yavar-70A, a novel water-in-oil adjuvant: A potency study in HPV-16E7d vaccine model |
| title_sort | yavar 70a a novel water in oil adjuvant a potency study in hpv 16e7d vaccine model |
| topic | hpv-16-e7d ifn-γ oil adjuvants vaccine formulation yavar-70a |
| url | https://ijbms.mums.ac.ir/article_25265_071c9e5e07dfbd3e4525287c835ce198.pdf |
| work_keys_str_mv | AT zeinabmirzaei yavar70aanovelwaterinoiladjuvantapotencystudyinhpv16e7dvaccinemodel AT soyarsari yavar70aanovelwaterinoiladjuvantapotencystudyinhpv16e7dvaccinemodel AT masoudmoghaddampour yavar70aanovelwaterinoiladjuvantapotencystudyinhpv16e7dvaccinemodel AT seyedmehdihassanzadeh yavar70aanovelwaterinoiladjuvantapotencystudyinhpv16e7dvaccinemodel AT benjamindamizadeh yavar70aanovelwaterinoiladjuvantapotencystudyinhpv16e7dvaccinemodel AT mortezataghizadeh yavar70aanovelwaterinoiladjuvantapotencystudyinhpv16e7dvaccinemodel AT mehdimahdavi yavar70aanovelwaterinoiladjuvantapotencystudyinhpv16e7dvaccinemodel |